ArticleGastroenterology report2026
Impact of incisura biopsy on the surveillance of precursor lesions and gastric cancer risk assessment.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnostic value of an incisura biopsy during upper gastrointestinal endoscopies (UGEs) for detecting gastric cancer precursor lesions (GCPLs) remains debated. This study aimed to evaluate the impact of incisura biopsy on the detection of GCPL, staging according to Operative Link for Gastritis Assessment (OLGA) and Operative Link of Gastritis and Intestinal Metaplasia (OLGIM), and surveillance strategies. Methods: This observational, single-centre retrospective study included patients undergoing UGE between 2017 and 2022 with gastric biopsies from the corpus, antrum, and incisura in separate vials, and intestinal metaplasia (IM) identified in at least one site. OLGA/OLGIM stages were assessed with and without the incisura biopsy. Factors associated with stage or surveillance modifications were analysed. Results: Among 27,166 patients undergoing UGEs, 819 patients met the inclusion criteria. Of the 819 patients, the median age was 67 years (interquartile range, 59-74 years), 59.5% were women, 89.3% originated from low gastric cancer (GC) risk regions, and 35.6% had current or prior Conclusions: Adding an incisura biopsy to gastric mapping identified more advanced GCPL, upstaged OLGA/OLGIM in ∼20% of patients, and increased surveillance recommendations in an extra ∼10%. These results recommend the systematic inclusion of the incisura biopsy in GC risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.